Investment Analysts’ updated eps estimates for Friday, January 5th:

Abcam (LON:ABC) had its buy rating reissued by analysts at Berenberg Bank. They currently have a GBX 1,240 ($16.58) target price on the stock.

ABLYNX (OTCMKTS:ABLYF) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Ablynx NV is a biopharmaceutical company which engaged in the development of Nanobodies (R) proprietary therapeutic proteins based on single-domain antibody fragments. The company also discovers and develops therapeutic for inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx NV is headquartered in Ghent, Belgium. “

Adamas Pharmaceuticals (NASDAQ:ADMS) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “

Akcea Therapeutics (NASDAQ:AKCA) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company’s drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx which are in clinical stage. Akcea Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Akzo Nobel (OTCMKTS:AKZOY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “AkzoNobel is a leading global paints and coatings company and a major producer of specialty chemicals. Their portfolio includes brands such as Dulux, Sikkens, International, Interpon and Eka. “

Arkema (OTCMKTS:ARKAY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Arkema SA is engaged in the manufacturing and marketing of vinyl products, industrial chemicals, and performance products. Vinyl products include chlorine or caustic soda, pipes and profiles, PVC, and vinyl compounds. Industrial chemicals include emulsion systems, fluorochemicals, hydrogen peroxide, PMMA and methacrylics, specialty acrylic polymers and thiochemicals. Performance products include functional additives, specialty chemicals and technical polymers. The Company’s products can be used for various purposes including air conditioning or refrigeration; chemical processing, coating, construction; packaging; automotive & transportation. Its products, also find their application in adhesives and sealants, agriculture & agrochemicals, consumer goods, electronics, foams, solvents and aerosols market, health, hygiene & beauty, oil & gas, energy, pharmaceuticals, pulp & paper, rubber market, sports & leisure, etc. Arkema SA is headquartered in France. “

Aisin Seiki (OTCMKTS:ASEKY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Aisin Seiki Co., Ltd. is engages in the manufacture and sale of automotive parts. It operating segment consists of Aisin Seiki Group, Aisin Takaoka Group, Aisin AW Group, Advics Group and Others. Aisin Seiki Group segment provides general automotive parts and services, life and amenity-related equipment, public works and petroleum sales. Aisin Takaoka Group segment handles engine and brake cast components. Aisin AW Group deals with automatic transmissions and car navigation systems. Advics Group segment offers brake components. Others segment includes automotive parts lineup, energy systems, mainstay products for the major group companies, life and amenity products. Aisin Seiki Co., Ltd. is headquartered in Kariya, Japan. “

Centrica (LON:CNA) was upgraded by analysts at Credit Suisse Group AG to an outperform rating. They currently have GBX 170 ($2.27) target price on the stock.

Core-Mark (NASDAQ:CORE) was upgraded by analysts at Raymond James Financial, Inc. to a buy rating. The firm currently has $31.00 price target on the stock.

Core-Mark (NASDAQ:CORE) was upgraded by analysts at UBS Group AG from an outperform rating to a strong-buy rating.

First Analysis assumed coverage on shares of Catalent (NYSE:CTLT). They issued an equal weight rating on the stock.

Debenhams (LON:DEB) had its target price cut by Berenberg Bank from GBX 37 ($0.49) to GBX 19 ($0.25). The firm currently has a sell rating on the stock.

Debenhams (LON:DEB) had its price target trimmed by Canaccord Genuity from GBX 44 ($0.59) to GBX 28 ($0.37). Canaccord Genuity currently has a hold rating on the stock.

Debenhams (LON:DEB) had its price target reduced by Investec from GBX 34 ($0.45) to GBX 28 ($0.37). Investec currently has a hold rating on the stock.

easyJet (LON:EZJ) had its outperform rating reaffirmed by analysts at Credit Suisse Group AG. They currently have a GBX 1,565 ($20.93) target price on the stock.

Gem Diamonds (LON:GEMD) had its speculative buy rating reaffirmed by analysts at Canaccord Genuity. The firm currently has a GBX 95 ($1.27) target price on the stock.

Group 1 Automotive (NYSE:GPI) was upgraded by analysts at Buckingham Research from a neutral rating to a buy rating. Buckingham Research currently has $89.00 target price on the stock.

HTG Molecular Diagnostics (NASDAQ:HTGM) had its price target boosted by Canaccord Genuity to $5.00.

Intercept Pharmaceuticals (NASDAQ:ICPT) had its buy rating reissued by analysts at Wedbush. They currently have a $253.00 target price on the stock.

IQE (LON:IQE) had its buy rating reaffirmed by analysts at Canaccord Genuity. Canaccord Genuity currently has a GBX 190 ($2.54) price target on the stock.

Johnson Service Group (LON:JSG) had its target price increased by Investec from GBX 160 ($2.14) to GBX 170 ($2.27). The firm currently has a buy rating on the stock.

WM Morrison Supermarkets (LON:MRW) had its target price reduced by UBS Group AG from GBX 240 ($3.21) to GBX 230 ($3.08). The firm currently has a neutral rating on the stock.

Pagegroup (LON:PAGE) was downgraded by analysts at Morgan Stanley to an underweight rating.

Synthomer (LON:SYNT) had its price target raised by Canaccord Genuity from GBX 525 ($7.02) to GBX 575 ($7.69). The firm currently has a buy rating on the stock.

United Utilities Group (LON:UU) was upgraded by analysts at Credit Suisse Group AG to a neutral rating. Credit Suisse Group AG currently has GBX 850 ($11.37) target price on the stock.

William Hill (LON:WMH) was upgraded by analysts at Canaccord Genuity to a buy rating. The firm currently has GBX 350 ($4.68) target price on the stock, up from their previous target price of GBX 285 ($3.81).

Receive News & Ratings for Abcam Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam Plc and related companies with MarketBeat.com's FREE daily email newsletter.